ScinoPharm Taiwan Ltd banner

ScinoPharm Taiwan Ltd
TWSE:1789

Watchlist Manager
ScinoPharm Taiwan Ltd Logo
ScinoPharm Taiwan Ltd
TWSE:1789
Watchlist
Price: 21.6 TWD 1.89% Market Closed
Market Cap: NT$17.1B

ScinoPharm Taiwan Ltd
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ScinoPharm Taiwan Ltd
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
ScinoPharm Taiwan Ltd
TWSE:1789
Research & Development
-NT$497.3m
CAGR 3-Years
-22%
CAGR 5-Years
-15%
CAGR 10-Years
-4%
Y
YungShin Global Holding Corp
TWSE:3705
Research & Development
-NT$401m
CAGR 3-Years
-4%
CAGR 5-Years
0%
CAGR 10-Years
-1%
Formosa Laboratories Inc
TWSE:4746
Research & Development
-NT$706.2m
CAGR 3-Years
2%
CAGR 5-Years
-6%
CAGR 10-Years
-13%
Lotus Pharmaceutical Co Ltd
TWSE:1795
Research & Development
-NT$986.7m
CAGR 3-Years
-24%
CAGR 5-Years
-20%
CAGR 10-Years
-13%
Standard Chem & Pharm Co Ltd
TWSE:1720
Research & Development
-NT$257.7m
CAGR 3-Years
-1%
CAGR 5-Years
-3%
CAGR 10-Years
-1%
C
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
Research & Development
-NT$650.5m
CAGR 3-Years
-30%
CAGR 5-Years
-49%
CAGR 10-Years
N/A
No Stocks Found

ScinoPharm Taiwan Ltd
Glance View

Market Cap
17.1B TWD
Industry
Pharmaceuticals

ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.

Intrinsic Value
14.24 TWD
Overvaluation 34%
Intrinsic Value
Price NT$21.6

See Also

What is ScinoPharm Taiwan Ltd's Research & Development?
Research & Development
-497.3m TWD

Based on the financial report for Dec 31, 2025, ScinoPharm Taiwan Ltd's Research & Development amounts to -497.3m TWD.

What is ScinoPharm Taiwan Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-4%

Over the last year, the Research & Development growth was -8%. The average annual Research & Development growth rates for ScinoPharm Taiwan Ltd have been -22% over the past three years , -15% over the past five years , and -4% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett